molidustat
Ligand Summary
Molidustat (BAY 85–3934) is a novel, orally bioavailable HIF-PH inhibitor that mimics hypoxia by stabilizing HIF-a subunits. Molidustat inhibits HIF-PH, allowing the accumulation of HIF, which then translocates to the nucleus where it activates the transcription of erythropoietin (EPO) and other hypoxia-inducible genes, thereby increasing endogenous EPO levels and formation of the red blood cell.
PubChem: 59603622
PubChem: 69669724
Guide to Pharmacology: 8456
ChEMBL: CHEMBL3646118
ChEMBL: CHEMBL3931782
DrugCentral: 5486
LyCHI: XQ6L4GR3W4QR
Target Activities
14 Activities
Items per page:
1 – 10 of 14
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||